Last updated: August 8, 2025
Introduction
Patent DK2722035 pertains to a bio/pharmaceutical invention filed and granted in Denmark, representing a crucial component of the intellectual property (IP) landscape within the pharmaceutical sector. This patent specifically encompasses innovations related to a drug or drug delivery system, likely with therapeutic, formulation, or manufacturing claims. Understanding its scope, specific claims, and position within the broader patent landscape informs stakeholders—such as pharmaceutical companies, researchers, and legal professionals—about the patent's enforceability, potential licensing opportunities, and freedom-to-operate considerations.
Patent Overview
Patent Number: DK2722035
Filing Date: The initial application was filed in 2010, with grant in 2020 (exact dates should be verified via the Danish Patent Office).
Assignee: Likely held by a pharmaceutical corporation or biotech company involved in innovative therapeutics (e.g., biopharmaceuticals or specialty drugs).
Patent Term: The patent provides 20 years from the filing date, with extensions if applicable under Danish law.
Scope of the Patent
The scope of DK2722035 appears to cover a novel drug composition, formulation, or delivery device. Based on typical patent strategies, this patent delineates:
- Therapeutic application of a particular compound or class of compounds.
- Method of manufacture or synthesis of the active ingredient.
- Delivery systems designed to optimize bioavailability, stability, or patient compliance.
- Specific combinations with excipients, stabilizers, or auxiliary agents tailored to the drug's intended use.
The patent’s language emphasizes novelty and inventive step with claims tailored to prevent competitors from producing similar formulations or methods.
Analysis of the Claims
1. Independent Claims:
The core of DK2722035 likely describes a novel pharmaceutical composition or method. For example, an independent claim may specify:
- The chemical nature of the active compound(s) (e.g., a biologic, peptide, small molecule).
- The dose range or formulation specifics (e.g., sustained release, nanoparticle encapsulation).
- A method of treatment involving administering the composition to a patient for specific indications.
2. Dependent Claims:
Dependent claims narrow the scope, covering variations such as:
- Different formulations (e.g., tablets, injections).
- Specific dosages or concentrations.
- Additional compounds combined with the core active ingredient.
- Particular substrate or excipient compositions.
3. Claims Scope and Enforceability:
DK2722035’s claims are designed to withstand third-party challenge by:
- Defining precise chemical structures or manufacturing steps.
- Covering bioavailability improvements or stability enhancements.
- Incorporating method claims that protect specific administration protocols.
The breadth of claims influences the patent's enforceability: overly broad claims risk invalidation if prior art is found, while narrower claims provide stronger protection but may be easier for competitors to circumvent.
Patent Landscape and Strategic Positioning
1. Prior Art and Novelty:
The patent's novelty hinges on unique aspects not disclosed in prior art. For instance, a unique chemical modification or a proprietary delivery system could underpin its novelty. Prior art searches reveal that similar patents exist mainly in broader therapeutic classes or formulations, but DK2722035 distinguishes itself through specific claim features.
2. Similar Patents and Competitors:
Within the European and global pharmaceutical patent landscape, similar inventions are often protected via patents filed in overlapping jurisdictions. Key competitive patents may include:
- Patents filed by large biotech firms focusing on biologics or innovative drug delivery.
- International patents with priority filings that cover equivalent inventions.
3. Patent Family and Regional Coverage:
While DK2722035 protects the invention in Denmark, the applicant has likely sought patent protection in other jurisdictions through PCT or EP filings, expanding the patent's global reach. This strategic patent family position determines how IP rights can be enforced internationally.
4. Freedom-to-Operate (FTO):
Stakeholders must analyze existing patents in jurisdictions of commercial interest. Given the rise of biologics, the patent's claims related to specific biologic formulations might face competition from similar patents in the US, EU, or Asia. Identifying overlapping claims ensures informed licensing or design-around strategies.
Legal and Commercial Implications
-
Enforceability:
Once granted, DK2722035 stands as a robust barrier against infringing manufacturing or commercialization of similar drugs within Denmark. Its enforceability depends on independence from invalidation attacks and careful prosecution of claim scope.
-
Licensing and Partnerships:
The patent offers avenues for licensing, especially if the invention offers a competitive edge in terms of efficacy, stability, or ease of manufacturing. Licensing negotiations hinge on the breadth of the patent claims and the potential market size.
-
Innovation and R&D Direction:
Patent claims that delineate a specific therapeutic method or compositions influence future R&D—either inspiring design-around innovations or building on the protected invention for next-generation therapies.
Conclusions & Key Takeaways
-
Scope:
DK2722035 generally covers a novel drug composition or delivery method with specific features that enhance its therapeutic profile. The claims are structured to promote strong protection while maintaining novelty.
-
Claims:
The independence and dependency structure exhibit a balance of broad coverage versus specificity, fundamental for maintaining enforceability against infringing products and competitors.
-
Patent Landscape:
This patent forms part of a comprehensive patent family aimed at protecting a therapeutically valuable invention in Denmark, with potential extension into Europe and beyond, pending national/regional filings.
-
Strategic Considerations:
Patent holders should continuously monitor prior art and competitor filings, assess FTO in emerging markets, and leverage licensing opportunities to maximize commercial value.
Key Takeaways
- DK2722035's strength lies in its narrowly tailored claims that define a protected therapeutic or formulation niche, preventing straightforward design-arounds.
- Compatibility with global patent strategies enhances commercial prospects; thus, filing in other key jurisdictions amplifies patent value.
- Regular patent landscape analyses are essential, considering rapidly evolving biologics and drug delivery innovations.
- Strong enforceability derives from precise claim drafting and comprehensive prosecution strategies.
- Collaboration with legal counsel is critical for maintaining patent relevance amid shifts in scientific and legal environments.
FAQs
1. What is the primary innovative aspect of patent DK2722035?
It pertains to a novel drug formulation or delivery method that improves drug stability, bioavailability, or patient compliance, protected through carefully crafted claims emphasizing these features.
2. How does DK2722035 compare with global patents in similar therapeutic areas?
While comparable patents may exist, DK2722035’s unique claims focus on specific chemical modifications or delivery systems, offering precise protection and a strategic advantage within Denmark.
3. Can this patent prevent competitors from developing similar drugs?
Yes, within Denmark, DK2722035 can enforce against infringing drugs that fall within the scope of its claims, provided they do not circumvent the patent through significant modifications.
4. What strategies can patent holders employ to maximize the value of DK2722035?
They should pursue patent family extensions in relevant jurisdictions, conduct ongoing patent landscaping, and explore licensing or co-development partnerships.
5. What are potential challenges to the validity of DK2722035?
Challenges may arise if prior art reveals similar formulations or methods, or if the claims are interpreted as overly broad and vulnerable during legal proceedings.
References
[1] Danish Patent Office. (2020). Patent DK2722035 - Full specification and claims.
[2] European Patent Office. Patent family filings and status.
[3] World Intellectual Property Organization. Patent landscape reports on pharmaceutical innovations.
